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Edited by Laszlo NagyAbstract Tissue inhibitor of metalloproteinase (TIMP)-1 is an
adipocyte-secreted protein upregulated in obesity which pro-
motes adipose tissue development. Furthermore, the proinﬂam-
matory adipocytokines tumor necrosis factor a (TNFa) and
interleukin (IL)-6 induce insulin resistance, and plasma concen-
trations are increased during weight gain. In the current study,
the impact of TNFa and IL-6 on TIMP-1 mRNA and protein
expression was determined in 3T3-L1 adipocytes. Interestingly,
TNFa and IL-6 induced TIMP-1 protein secretion more than
3- and 2-fold, respectively. Furthermore, TIMP-1 mRNA was
upregulated in a time- and dose-dependent fashion. Inhibitor
experiments suggested that nuclear factor jB and p44/42 mito-
gen-activated protein kinase are involved in both, basal and
adipocytokine-induced TIMP-1 expression. Moreover, the thia-
zolidinedione troglitazone partly reversed TNFa- but not IL-6-
induced TIMP-1 synthesis. Taken together, we demonstrate that
TIMP-1 expression is selectively upregulated in fat cells by pro-
inﬂammatory adipocytokines and might play a role in maintain-
ing adipose tissue mass in obesity.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Obesity is a rapidly growing nutritional disorder character-
ized by excessive accumulation of adipose tissue [1]. Both,
hyperplasia and hypertrophy of adipocytes can be found when
weight is gained [1]. Furthermore, neovascularization of
expanding adipose tissue is critical to maintain proper function
[2]. These multiple processes depend on dynamic changes of
cell–matrix interactions and extensive extracellular matrixAbbreviations: ECM, extracellular matrix; IL-6, interleukin-6; IR,
insulin receptor; MAP, mitogen-activated protein; MMP, matrix me-
talloproteinase; NFjB, nuclear factor jB; PI, phosphatidylinositol;
PPAR, peroxisome proliferator-activated receptor; TIMP, tissue
inhibitor of matrix metalloproteinase; TNF, tumor necrosis factor
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doi:10.1016/j.febslet.2005.10.033(ECM) remodeling [3]. Various members of the matrix
metalloproteinase (MMP) family and the tissue inhibitors of
MMPs (TIMPs) appear as primary mediators of ECM remod-
eling [3]. MMPs consist of more than 20 neutral endopeptid-
ases which are able to cleave ECM components and several
non-ECM proteins including cytokines, adhesion molecules,
and proteinase inhibitors [3]. MMP activity is inhibited
through interaction with TIMPs which comprise a family of
four members [3].
The potential contribution of MMPs and TIMPs to obesity-
related adipose tissue enlargement has been determined
recently, and TIMP-1 appears as an interesting candidate
promoting fat accumulation for several reasons. First, two
independent studies reported signiﬁcant upregulation of adi-
pose tissue TIMP-1 in mice with genetically based or diet-
induced obesity [4,5]. Furthermore, transgenic overexpression
of TIMP-1 increased the rate of adipocyte diﬀerentiation
in vivo [6]. In accordance with these ﬁndings, treatment of
3T3-L1 cells with recombinant TIMP-1 dramatically acceler-
ated lipid accumulation during diﬀerentiation in vitro [6].
Moreover, TIMP-1-deﬁcient mice were protected from nutri-
tionally induced obesity [7]. Thus, TIMP-1 appears as a novel
fat-derived protein promoting adipose tissue development
when weight is gained. However, it is unclear so far which
mediators stimulate TIMP-1 expression in fat cells in obesity.
During weight gain, the proinﬂammatory adipocytokines
tumor necrosis factor a (TNFa) and interleukin (IL)-6 show
increased expression in fat, and plasma concentrations corre-
late with the development of glucose intolerance [8]. In the cur-
rent study, we, therefore, examined the eﬀect of these cytokines
on TIMP-1 expression and secretion in 3T3-L1 adipocytes
in vitro. We demonstrate for the ﬁrst time that both adipocy-
tokines signiﬁcantly stimulate TIMP-1 mRNA and protein
synthesis in fat cells. Furthermore, we present evidence that
basal and adipocytokine-induced TIMP-1 expression is medi-
ated via nuclear factor jB (NFjB) and p44/42 mitogen-acti-
vated protein (MAP) kinase. Moreover, troglitazone partly
reverses TNFa- but not IL-6-stimulated TIMP-1.2. Materials and methods
2.1. Materials
Cell culture reagents were obtained from Life Technologies, Inc.
(Grand Island, NY), oligonucleotides from MWG-Biotech (Ebersberg,
Germany). Dexamethasone, IL-6, insulin, isobutylmethylxanthine,
LY294002, parthenolide, PD98059, SB203580, TNFa, and troglitazoneblished by Elsevier B.V. All rights reserved.
6418 S. Kralisch et al. / FEBS Letters 579 (2005) 6417–6422were purchased from Sigma Chemical Co. (St. Louis, MO). Antibodies
detecting phospho- or total p44/42 MAP kinase were from Cell Signal-
ing Technology (Beverly, MA, USA).2.2. Culture and diﬀerentiation of 3T3-L1 cells
3T3-L1 cells (American Type Culture Collection, Rockville, MD)
were diﬀerentiated as described [9]. In brief, conﬂuent preadipocytes
were cultured for three days in DMEM containing 25 mM glucose
(DMEM-H), 10% fetal bovine serum, and antibiotics (culture medium)
further supplemented with 1 lM insulin, 0.5 mM isobutylmethylxan-
thine, and 0.1 lM dexamethasone. After this period, they were grown
for three days in culture medium with 1 lM insulin and for three to six
more days in culture medium. Various eﬀectors were added to cells
starved in DMEM-H only for the indicated periods of time. At the
time of the stimulation experiments at least 95% of the cells had accu-
mulated fat droplets.2.3. Analysis of TIMP-1 and TIMP-2 mRNA
TIMP mRNA synthesis was determined by quantitative real-time
RT-PCR in a ﬂuorescent temperature cycler (ABI Prism 7000, Ap-
plied Biosystems, Darmstadt, Germany) as described previously
[10]. Brieﬂy, total RNA was isolated from 3T3-L1 adipocytes with
TRIzol reagent (Life Technologies, Inc., Grand Island, NY) and
1 lg RNA was reverse transcribed using standard reagents (Life
Technologies, Inc., Grand Island, NY). 2 ll of each RT reaction
was ampliﬁed in a 26 ll PCR. After initial denaturation at 95 C
for 10 min, 40 PCR cycles were performed using the following con-
ditions: 95 C for 15 s, 60 C for 1 min, and 72 C for 1 min. The
following primer pairs were used: TIMP-1 (Accession No.
NM_011593) CTATAGTGCTGGCTGTGGGGTGTG (sense) and
TTCCGTGGCAGGCAAGCAAAGT (antisense); TIMP-2 (Acces-
sion No. NM_011594) GGCCTCCCTCCCTTACTCC (sense) and
GACTTCATATTCCAGCACGCACAT (antisense); 36B4 (Acces-
sion No. NM007475) AAGCGCGTCCTGGCATTGTCT (sense)
and CCGCAGGGGCAGCAGTGGT (antisense). SYBR Green I
ﬂuorescence emissions were monitored after each cycle and synthesis
of TIMP-1, TIMP-2, and 36B4 mRNA was quantiﬁed using the sec-
ond derivative maximum method of the ABI Prism 7000 software
(Applied Biosystems, Darmstadt, Germany). This method deter-
mines the crossing points of individual samples by an algorithm
identifying the ﬁrst turning point of the ﬂuorescence curve. TIMP-
1 and TIMP-2 expression was calculated relative to 36B4 which
was used as an internal control due to its resistance to hormonal
regulation [11]. Speciﬁc transcripts were conﬁrmed by melting curve
proﬁles (cooling the sample to 68 C and heating slowly to 95 C
with measurement of ﬂuorescence) at the end of each PCR and
the speciﬁcity of the PCR was further veriﬁed by subjecting the
ampliﬁcation products to agarose gel electrophoresis.2.4. Analysis of TIMP-1 secretion
Quantiﬁcation of TIMP-1 protein levels in 3T3-L1 cell culture super-
natants was performed with a commercially available enzyme-linked
immunoassay (ELISA) from RayBiotech Inc. (Norcross, GA, USA)
according to the manufacturers instructions.2.5. Western blotting
Western blotting was performed essentially as described [12].
Brieﬂy, cells were harvested in lysis buﬀer (50 mM HEPES,
137 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 10 mM Na4P2O7,
10 mM NaF, 2 mM EDTA, 10% glycerol, 1% Igepal CA-630,
2 mM vanadate, 2 mM phenylmethylsulfonyl ﬂuoride, 10 lg/ml leu-
peptin, 10 lg/ml aprotinin, pH 7.4) and lysates were clariﬁed. Equal
amounts of protein were resolved by SDS–PAGE, transferred to
nitrocellulose membranes, blocked for 1 h, and immunoblotted with
p44/42 MAP kinase antibodies for 2 h. Speciﬁcally bound primary
antibodies were detected with peroxidase-coupled secondary anti-
body and enhanced chemiluminescence.2.6. Statistical analysis
Results are shown as means ± SE. Diﬀerences between various treat-
ments were analyzed by unpaired Students t tests with P values <0.01
considered highly signiﬁcant and <0.05 considered signiﬁcant.3. Results
3.1. TIMP-1 secretion is stimulated by TNFa and IL-6
TIMP-1 secretion into the medium was determined in diﬀer-
entiated 3T3-L1 cells after TNFa (20 ng/ml) and IL-6 (30 ng/
ml) treatment for 16 h. Interestingly, both eﬀectors signiﬁ-
cantly increased TIMP-1 protein levels in the supernatants
from 28.3 (basal) to 89.6 ng/ml (TNFa) and 61.7 ng/ml (IL-
6), respectively (P < 0.01) (Fig. 1).3.2. TIMP-1 but not TIMP-2 mRNA is induced by TNFa and
IL-6 in 3T3-L1 adipocytes
Next, we tested whether TNFa and IL-6 might inﬂuence
TIMP-1 or TIMP-2 mRNA expression in 3T3-L1 adipocytes.
In fact, both proinﬂammatory cytokines induced TIMP-1 in
a time-dependent fashion (Fig. 2). Thus, signiﬁcant 4.8-fold
stimulation was ﬁrst seen after 4 h of TNFa treatment, and
activation persisted for up to 24 h (P < 0.01) (Fig. 2A). Fur-
thermore, signiﬁcant 1.6-fold upregulation of TIMP-1 was evi-
dent as early as 1 h after IL-6 addition (P < 0.05) and maximal
5.1-fold stimulation was observed after 24 of treatment
(P < 0.01) (Fig. 2B). In contrast, TIMP-2 mRNA was not sig-
niﬁcantly regulated by TNFa and IL-6 (Fig. 2A and B).
TNFa and IL-6-induced TIMP-1 synthesis dose-dependently
after 16 h of treatment (Fig. 3). Thus, signiﬁcant stimulationwas
seen at concentrations as low as 3 ng/ml TNFa (P < 0.05)
(Fig. 3A) and 10 ng/ml IL-6 (P < 0.05) (Fig. 3B). Furthermore,
maximal eﬀects were detectable at 100 ng/ml eﬀector for both,
TNFa (P < 0.01) (Fig. 3A) and IL-6 (P < 0.05) (Fig. 3B). Treat-
ment of 3T3-L1 adipocytes with 20 ng/ml TNFa or 30 ng/ml IL-
6 for 16 h did not aﬀect adipocyte diﬀerentiation as assessed by
oil red O staining (data not shown).3.3. NFjB and p44/42 MAP kinase are involved in basal and
adipocytokine-induced TIMP-1 expression
Various eﬀects of proinﬂammatory TNFa and IL-6 are med-
iated via NFjB. To determine whether this signaling interme-
diate was involved in TIMP-1 induction, 3T3-L1 adipocytes
were pretreated with parthenolide (50 lM), a speciﬁc pharma-
cological NFjB inhibitor for 1 h before TNFa (20 ng/ml,
Fig. 4A) and IL-6 (30 ng/ml, Fig. 4B) were added for 16 h. Par-
thenolide signiﬁcantly downregulated basal TIMP-1 expres-
sion to 63% of controls (P < 0.01) (Fig. 4A and B). Again,
TNFa (Fig. 4A) and IL-6 (Fig. 4B) signiﬁcantly induced
TIMP-1 expression 12.2- and 3.7-fold, respectively
(P < 0.01). Interestingly, this induction was signiﬁcantly re-
versed to 86% (TNFa, P < 0.01, Fig. 4A) and 159% (IL-6,
P < 0.01, Fig. 4B) of control levels. Treatment of 3T3-L1 adi-
pocytes with both, TNFa and IL-6, did not signiﬁcantly aug-
ment TIMP-1 mRNA beyond the level seen with TNFa
stimulation alone (Fig. 4A).
We next tested whether signaling proteins such as p44/42
MAP kinase, p38 MAP kinase, and phosphatidylinositol (PI)
3-kinase might play a role in stimulation of TIMP-1 synthesis.
For this purpose, 3T3-L1 adipocytes were pretreated with spe-
ciﬁc pharmacological inhibitors for 1 h before TNFa (20 ng/
ml, Fig. 5A) and IL-6 (30 ng/ml, Fig. 5B) were added for
16 h. Interestingly, the p44/42 MAP kinase inhibitor
PD98059 (50 lM) and the PI 3-kinase inhibitor LY294002
(10 lM) alone signiﬁcantly downregulated basal TIMP-1 syn-
thesis to 43% and 61% of the levels seen in untreated control
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Fig. 1. TIMP-1 secretion is stimulated by TNFa and IL-6. 3T3-L1 cells
were serum-starved for 6 h before TNFa (TNF, 20 ng/ml) and IL-6
(30 ng/ml) were added for 16 h. After this period, TIMP-1 secretion into
themediumwas determined by ELISA as described in Section 2. Results
are the means ± SEM of three independent experiments. \\ denotes
P < 0.01 comparing eﬀector-treated with untreated adipocytes.
S. Kralisch et al. / FEBS Letters 579 (2005) 6417–6422 6419cells, respectively (P < 0.05) (Fig. 5A and B). In contrast, inhi-
bition of p38 MAP kinase with SB203580 (20 lM) did not sig-
niﬁcantly inﬂuence basal TIMP-1 mRNA (Fig. 5A and B).
TIMP-1 mRNA was stimulated 6.5-fold after 16 h of TNFa
0
1 10 100 1000
IL-6 (ng/ml)
Con
Fig. 3. Dose-dependent upregulation of TIMP-1 mRNA by TNFa
and IL-6. Diﬀerentiated 3T3-L1 cells were serum-starved for 6 h before
various concentrations of (A) TNFa and (B) IL-6 were added for 16 h.
Extraction of total RNA and quantitative real-time RT-PCR deter-
mining TIMP-1 mRNA levels normalized to 36B4 expression were
performed as described in Section 2. Data are shown relative to
untreated control (Con) cells (= 100%) and represent the means ±
SEM of at least three independent experiments. \\ denotes P < 0.01,
\ P < 0.05 comparing hormone-treated with untreated control cells.
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Fig. 2. Time-dependent stimulation of TIMP-1 but not TIMP-2
synthesis by TNFa and IL-6. After serum-deprivation overnight, 3T3-
L1 fat cells were treated with (A) TNFa (TNF, 20 ng/ml) and (B) IL-6
(30 ng/ml) for the indicated periods of time. Total RNA was extracted
and subjected to quantitative real-time RT-PCR as described in
Section 2. TIMP-1 and TIMP-2 mRNA levels normalized to 36B4
expression were determined relative to untreated control cells
(= 100%). Data represent the means of at least three independent
experiments. \\ denotes P < 0.01, \ P < 0.05 comparing hormone-
treated with non-treated adipocytes.treatment (P < 0.01) (Fig. 5A). Interestingly, inhibition of
p44/42 MAP kinase by PD98059 signiﬁcantly reversed this
activation by 76–154% of the expression seen in untreated adi-
pocytes (P < 0.05) (Fig. 5A). In contrast, inhibition of p38
MAP kinase and PI 3-kinase did not signiﬁcantly inﬂuence
stimulation of TIMP-1 synthesis by TNFa (Fig. 5A). IL-6
upregulated TIMP-1 mRNA 2.2-fold as compared to controls
(P < 0.01) (Fig. 5B). Again, PD98059-pretreatment signiﬁ-
cantly reversed this activation by more than 50–109% of con-
trol expression (P < 0.05) (Fig. 5B). In contrast, LY294002
and SB203580 did not signiﬁcantly inﬂuence stimulation of
TIMP-1 by IL-6 (Fig. 5B). Furthermore, we determined
whether TNFa directly stimulates p44/42 MAP kinase phos-
phorylation. Treatment of 3T3-L1 adipocytes with 20 ng/ml
TNFa time-dependently increased phosphorylation of p44/42
MAP kinase with maximal eﬀects detectable 15 min after eﬀec-
tor addition (Fig. 5C). Furthermore, TNFa-induced p44/42
MAP kinase phosphorylation could be completely inhibited
by pretreatment with 50 lM PD98059 for 17 h (Fig. 5D).
3.4. Troglitazone partly reverses TNFa- but not IL-6-induced
TIMP-1 expression
Insulin-sensitizing thiazolidinediones have been shown to
prevent certain actions of proinﬂammatory TNFa and IL-6
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Fig. 4. NFjB inﬂuences basal and cytokine-induced TIMP-1 expres-
sion. After 5 h serum-starvation, diﬀerentiated 3T3-L1 adipocytes were
cultured in the presence or absence of parthenolide (Part, 50 lM) for
1 h before TNFa (20 ng/ml) and/or IL-6 (30 ng/ml) were added for
additional 16 h. Total RNA was extracted and quantitative real-time
RT-PCR was performed as described in Section 2. TIMP-1 mRNA
expression is shown normalized to 36B4 and relative to untreated
control (Con) cells (= 100%). Results are the means ± SEM of four
independent experiments. \\ denotes P < 0.01 comparing TNFa- or IL-
6-treated cells with untreated or parthenolide-pretreated adipocytes or
comparing untreated with parthenolide-pretreated cells. The last
column in Fig. 4A represents the results of a combined treatment of
TNFa and IL-6.
Fig. 5. p44/42 MAP kinase inﬂuences basal and cytokine-induced
TIMP-1 expression. After 5 h serum-starvation, diﬀerentiated 3T3-L1
adipocytes were cultured in the presence or absence of PD98059 (PD,
50 lM), SB203580 (SB, 20 lM), or LY294002 (10 lM) for 1 h before
(A) TNFa (20 ng/ml) and (B) IL-6 (30 ng/ml) was added for additional
16 h. After total RNA extraction, quantitative real-time RT-PCR was
performed as described in Section 2. TIMP-1 mRNA expression
normalized to 36B4 is shown relative to untreated control (Con) cells
(= 100%). Results are the means ± SEM of three independent exper-
6420 S. Kralisch et al. / FEBS Letters 579 (2005) 6417–6422in 3T3-L1 adipocytes [22,23]. Therefore, we determined
whether the thiazolidinedione troglitazone might aﬀect stimu-
lation of TIMP-1 by TNFa and IL-6. Treatment of 3T3-L1
cells with 10 lM troglitazone signiﬁcantly reduced basal
TIMP-1 expression to 70% of controls (P < 0.01) (Fig. 6).
Again, TNFa and IL-6 upregulated TIMP-1 synthesis 7.3-
and 5.2-fold, respectively (P < 0.01) (Fig. 6). Interestingly,
TNFa-induced TIMP-1 expression was signiﬁcantly reversed
by about 50% by troglitazone pretreatment (P < 0.05)
(Fig. 6). In contrast, troglitazone did not inﬂuence IL-6-in-
duced TIMP-1 expression (Fig. 6).iments. \\ denotes P < 0.01, \P < 0.05 comparing untreated with
PD98059-, LY294002-, TNFa- or IL-6-treated cells or comparing
PD98059-pretreated with TNFa- or IL-6-treated adipocytes. TNFa
(TNF, 20 ng/ml) was added (C) for the indicated periods of time or (D)
for 15 min in the presence or absence of PD98059 pretreatment (PD,
50 lM, 17 h). Western blotting was performed as described in Section
2. Representative blots from at least two independent experiments are
shown.4. Discussion
In the current study, we show for the ﬁrst time that TIMP-1
but not TIMP-2 expression is induced in adipocytes by TNFa
and IL-6 in vitro. Since TNFa and IL-6 are increased during
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Fig. 6. Troglitazone partly reverses TNFa- but not IL-6-induced
TIMP-1 expression. After 5 h serum-starvation, diﬀerentiated 3T3-L1
adipocytes were cultured in the presence or absence of troglitazone
(Tro, 10 lM) for 1 h before TNFa (TNF, 20 ng/ml) or IL-6 (30 ng/ml)
were added for additional 16 h. Total RNA was extracted and
subjected to quantitative real-time RT-PCR as described in Section 2.
TIMP-1 mRNA synthesis normalized to 36B4 is expressed relative to
untreated control (Con) cells (= 100%). Results are the means ± SEM
of three independent experiments. xx denotes P < 0.01 comparing
untreated with troglitazone-treated cells. \\ denotes P < 0.01 compar-
ing untreated with TNFa- or IL-6-treated cells. \ denotes P < 0.05
comparing TNFa-treated with troglitazone-pretreated adipocytes.
S. Kralisch et al. / FEBS Letters 579 (2005) 6417–6422 6421weight gain [13,14], both adipocytokines appear as primary
stimulators leading to upregulation of TIMP-1 in fat seen in
obesity [4]. Furthermore, TIMP-1 overexpression accelerates
adipocyte diﬀerentiation in vivo and in vitro [6], and TIMP-1
deﬁciency protects from nutritionally induced obesity [7].
These ﬁndings suggest that TIMP-1 is not only a passively reg-
ulated protein but might actively maintain adipose tissue mass
in states of increased TNFa and IL-6 serum levels such as
obesity and insulin resistance. In contrast, TIMP-2 synthesis
is not altered by TNFa and IL-6 indicating that the eﬀect of
both proinﬂammatory cytokines is speciﬁc for TIMP-1. Fur-
thermore, in contrast to TIMP-1 no evidence has been pre-
sented so far indicating that TIMP-2 inﬂuences adipose
tissue physiology.
The mechanisms by which TIMP-1 promotes fat accumu-
lation are unclear, however, several studies have yielded
interesting results. Thus, TIMP-1 but not TIMP-2 has
growth-promoting activity in a wide range of cells and has
been postulated as a new serum growth factor [15]. A sec-
ond independent study shows signiﬁcant suppression of
apoptosis in B cells after TIMP-1 but not TIMP-2 treatment
[16]. Most interestingly, in both studies the eﬀect of TIMP-1
is not due to metalloproteinase inhibition [15,16] and the
synthetic MMP inhibitor BB-94 does not protect cells from
apoptosis [16]. These ﬁndings are of special interest since
pharmacological inhibition of MMPs, in contrast to
TIMP-1 addition, results in reduced adipogenesis in vitro
and in vivo [4,5,17,18]. Taken these studies into consider-
ation, TIMP-1 appears to maintain fat mass independent
of MMP inhibition possibly via increased proliferation
and/or decreased apoptosis. Clearly, more work is needed
to more thoroughly understand the mechanisms by which
TIMP-1 promotes fat accumulation.
Various proteins including NFjB, p44/42 MAP kinase, p38
MAP kinase and PI 3-kinase have been implicated as impor-tant molecules in both, TNFa and IL-6 signaling [19–21]. In
the current study, we show that pharmacological inhibition
of NFjB by parthenolide and p44/42 MAP kinase by
PD98059 signiﬁcantly reverses TNFa- and IL-6-induced
TIMP-1 expression but also downregulates basal TIMP-1 syn-
thesis. These data support both signaling proteins as principal
positive mediators of TIMP-1 gene expression. However, they
do not exclude the possibility that other signaling proteins
apart from NFjB and p44/42 MAP kinase might also mediate
some of the positive eﬀects of TNFa and IL-6 on TIMP-1
mRNA synthesis. Furthermore, we conﬁrm that TNFa po-
tently induces p44/42 MAP kinase phosphorylation in 3T3-
L1 adipocytes which is inhibited by PD98059 pretreatment.
Of note, similar results have been published by our group most
recently for IL-6 [10]. In addition, PI 3-kinase appears as a po-
sitive mediator of basal TIMP-1 expression since inhibition of
this signaling molecule downregulates TIMP-1. In contrast,
p38 MAP kinase does not play a role in TIMP-1 expression.
Furthermore, TNFa and IL-6 do not have synergistic eﬀects
on TIMP-1 expression.
Insulin-sensitizing thiazolidinediones activate peroxisome
proliferator-activated receptor (PPAR) c and prevent certain
actions of TNFa and IL-6 in 3T3-L1 adipocytes [22,23]. Thus,
troglitazone or pioglitazone reverse the reduction in insulin
receptor (IR) or IR substrate-1 phosphorylation caused by
TNFa [22]. Furthermore, rosiglitazone re-establishes insulin-
induced lipogenesis impaired by IL-6 [23]. Therefore, we have
determined in the current study whether the thiazolidinedione
troglitazone might also inﬂuence TNFa- and IL-6-induced
TIMP-1 synthesis. Interestingly, PPARc-activation by troglit-
azone partly reverses TNFa- but not IL-6-induced TIMP-1
expression implicating that this nuclear hormone receptor
might be involved in regulation of TIMP-1 by TNFa but not
IL-6.
In the current study, we have not determined direct eﬀects of
TIMP-1 on 3T3-L1 adipocytes. However, a study by Alexan-
der et al. [6] has demonstrated that treatment of 3T3-L1 cells
with recombinant TIMP-1 dramatically accelerates lipid accu-
mulation during diﬀerentiation in vitro.
Taken together, we demonstrate for the ﬁrst time that
TIMP-1 expression and secretion are selectively regulated in
adipocytes by proinﬂammatory adipocytokines and might play
a role in maintaining adipose tissue mass in obesity. Further
studies are needed to more clearly deﬁne the mechanisms by
which TIMP-1 promotes fat accumulation.Acknowledgements: This work was supported by a grant of the Deut-
sche Forschungsgemeinschaft (DFG, FA376/3-1) and the Deutsche
Diabetes Gesellschaft (DDG) to M.F.References
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